Home / Market News / $SNN

$SNN news and market catalysts

The 23 most recent market catalysts affecting $SNN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

23 catalysts 6 high impact 9 bullish 7 bearish Healthcare
Nov 16, 2026 Corporate Catalyst Neutral Impact 55
Smith & Nephew Announces Share Buyback Results
Smith & Nephew plc repurchased 1,061,205 of its ordinary shares between November 11 and November 13, 2026, at an aggregate cost of $16.45 million. This share buyback reduces the to…
Nov 12, 2026 Corporate Catalyst Bearish Impact 75
RBC Adjusts Smith & Nephew plc Price Target and Forecasts Following FY26 Guidance Cut
Smith & Nephew recently lowered its fiscal year 2026 guidance, prompting RBC Capital Markets to adjust its financial forecasts and price target for the company. This is a significa…
Nov 12, 2026 Corporate Catalyst Bullish Impact 75
secunet Reports Significant Revenue and Order Intake Growth for First Nine Months of 2026
secunet Security Networks AG announced significant revenue and order intake growth for the first nine months of 2026, with revenue up 19.3% and order intake up 25.0%. This strong t…
Nov 11, 2026 Corporate Catalyst Neutral Impact 60
Smith & Nephew Launches $250 Million Second Tranche of Share Buyback
Smith & Nephew announced the launch of the second $250 million tranche of its share buyback program. This action is a continuation of the company's stated capital allocation strate…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Price Target for Smith & Nephew
UBS has updated its financial outlook for Smith & Nephew, increasing the price target for its shares. This move indicates that UBS analysts see slightly more upside potential for t…
Nov 4, 2026 Corporate Catalyst Neutral Impact 65
Secunet Announces Plans for AI Cloud for Classified Information
Secunet has announced plans to develop an AI cloud platform for handling classified information, targeting government authorities. This initiative is significant because it opens u…
Nov 4, 2026 Corporate Catalyst Bearish Impact 92
Smith & Nephew Ends Merger Talks with Johnson & Johnson's Orthopedics Unit and Cuts 2026 Outlook
Smith & Nephew's announcement that merger talks with Johnson & Johnson's orthopedics unit have ended without an agreement is a significant corporate event. This is compounded by th…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Standard Nuclear, Inc. Awarded $6.99 Million ARPA-E Grant for TRISO Fuel Development
Standard Nuclear, Inc. received a $6.99 million grant from ARPA-E for its TRISO fuel development project, which aims to utilize recycled transuranic and uranium feedstock for high-…
Oct 28, 2026 Corporate Catalyst Neutral Impact 55
Study Analyzes Silicon in Unirradiated TRISO Particles
A University of Western Ontario study found silicon impurities in unirradiated TRISO fuel particles manufactured by Standard Nuclear, Inc. This discovery is significant because the…
Oct 23, 2026 Corporate Catalyst Bearish Impact 85
Johnson & Johnson Orthopedics Merger Talks with Smith & Nephew Collapse
Merger discussions between Johnson & Johnson's orthopedics business and Smith & Nephew have officially collapsed. The primary reason cited for the breakdown was a dispute over the …
Oct 23, 2026 Corporate Catalyst Bearish Impact 95
Smith & Nephew and Johnson & Johnson Orthopaedics Merger Talks Collapse
Merger negotiations between Smith & Nephew and Johnson & Johnson's orthopaedics division have officially collapsed, primarily due to a dispute over who would lead the combined enti…
Oct 6, 2026 Corporate Catalyst Bullish Impact 75
Smith+Nephew's CARTIHEAL AGILI-C Implant Now Commercially Available In Europe; Randomized Trial Data Show Superior Pain Relief And Functional Gains Over 5 Years Versus Debridement Or Microfracture
The commercial availability of Smith+Nephew's CARTIHEAL AGILI-C implant in Europe, supported by robust 5-year clinical data showing superior pain relief and functional gains, is a …
Sep 22, 2026 Corporate Catalyst Bullish Impact 65
Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System
Smith+Nephew's announcement of FDA 510(k) clearance and the completion of initial surgical cases for its LANDMARK Total Knee System is a positive development. This signifies a new …
Aug 31, 2026 Corporate Catalyst Neutral Impact 55
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating
BTIG analyst Ryan Zimmerman initiated coverage on Smith & Nephew (SNN) with a Neutral rating. This event is significant because new analyst coverage, especially from a prominent fi…
Aug 4, 2026 Corporate Catalyst Bearish Impact 85
Smith & Nephew shares are trading lower after the company reported H1 financial results and cut its FY26 sales guidance below estimates.
The headline signals a significant negative corporate catalyst for Smith & Nephew. Lowered FY26 sales guidance, especially below estimates, suggests a fundamental re-evaluation of …
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
CORRECTION: Smith & Nephew Lowers FY2026 Sales Guidance from $6.534B to $6.411B vs $6.565B Est
Smith & Nephew (SNN) announced a significant reduction in its FY2026 sales guidance, lowering it from $6.534 billion to $6.411 billion. This new forecast is also below the consensu…
Aug 4, 2026 Corporate Catalyst Bullish Impact 85
Smith+Nephew Expects 2026 Revenue Growth of Around 4% Vs. Previously of Approx 6%
Smith+Nephew's downgrade of its 2026 revenue growth expectations from approximately 6% to around 4% is a significant negative catalyst. This 200 basis point reduction implies a mat…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Smith & Nephew H1 Adj. EPS $0.48 Up From $0.43 YoY, Sales $3.097B Vs. $2.961B YoY
This headline is a significant corporate catalyst for Smith & Nephew, demonstrating robust financial health with increased adjusted EPS and sales. The positive year-over-year growt…
Jul 31, 2026 Corporate Catalyst Bearish Impact 75
Smith+Nephew shares are trading lower amid possible sympathy with Stryker after that company reported Q2 financial results and had BTIG and Piper Sandler lower their respective price targets on the stock.
This headline indicates a significant corporate catalyst impacting the medical device sector. Stryker's Q2 results, coupled with analyst downgrades, are creating negative sentiment…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo Classification
Smith+Nephew (SNN) has secured FDA De Novo classification for its TESSA Spatial Surgery System, a significant regulatory milestone. This approval allows SNN to commercialize a new …
Jul 16, 2026 Corporate Catalyst Neutral Impact 65
Standard Nuclear Shares Open For Trade At $13.50/Share; IPO Priced At $15/Share On 10M Shares
This headline signals a disappointing debut for Standard Nuclear, as its shares opened 10% below the IPO price. This immediate 'underpricing' suggests either overvaluation by the u…
Jul 16, 2026 Corporate Catalyst Neutral Impact 85
Standard Nuclear IPO Indicating $12/Share On 900K Shares; IPO Priced At $15/Share On 10M Shares
The significant increase in both the IPO price ($12 to $15) and the number of shares offered (900K to 10M) for Standard Nuclear suggests exceptionally strong investor demand, likel…
Jul 15, 2026 Corporate Catalyst Bullish Impact 75
Smith+Nephew shares are trading higher after the company announced the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose solution for laryngology.
The commercial launch of the LYNX COBLATION Laryngeal Wand is a significant positive catalyst for Smith+Nephew. This new product expands their portfolio and addresses a specific ma…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.